| Literature DB >> 31848139 |
Abdullah Al-Abcha1, Mian Harris Iftikhar2, Fawzi Abu Rous3, Heather Laird-Fick3.
Abstract
A 63-year-old woman with a medical history of chronic myelogenous leukaemia treated with dasatinib, chronic obstructive pulmonary disease and heart failure with preserved ejection fraction presented with difficulty in breathing. Chest X-ray showed large right-sided pleural effusion, which was confirmed on a CT angiogram of the chest. Echocardiogram showed an ejection fraction of 61% with moderate to severely dilated right ventricle and right ventricular systolic pressure of 60 mm Hg. Diagnostic and therapeutic thoracentesis was performed, and 2.2 L of pleural fluid was removed. Pleural fluid analysis was consistent with chylothorax. Significant symptomatic improvement was noted after thoracentesis. In the absence of an alternate explanation, chylothorax was attributed to dasatinib, which was switched to nilotinib. This resulted in resolution of her pleural effusions. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: dasatinib; haematology (drugs and medicines); respiratory medicine; unwanted effects / adverse reactions
Mesh:
Substances:
Year: 2019 PMID: 31848139 PMCID: PMC6936595 DOI: 10.1136/bcr-2019-231653
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X